# Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

[1]Pablo Mallaroni*, [1] Natasha L. Mason,[1]Johannes T. Reckweg, [1]Riccardo Paci, [2]Sabrina Ritscher, [2]Stefan W. Toennes, [1]Eef L. Theunissen,[1]Kim P.C. Kuypers, [1]Johannes G. Ramaekers*

**Author affiliations**
[1]Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, 6200 MD Maastricht, the Netherlands
[2]Institute of Legal Medicine, University Hospital, Goethe University, Frankfurt/Main, Germany

**Corresponding authors' emails***
p.mallaroni@maastrichtuniversity.nl, j.ramaekers@maastrichtuniversity.nl

**Conflict of interest**
None

## Abstract

2,5-dimethoxy-4-bromophenethylamine (2C-B) is a hallucinogenic phenethylamine derived from mescaline. Observational and preclinical data have suggested it to be capable of producing both subjective and emotional effects on par with other classical psychedelics and entactogens. Whereas it is the most prevalently used novel serotonergic hallucinogen to date, it's acute effects and distinctions from classical progenitors have yet to be characterised in a controlled study. We assessed for the first time the immediate acute subjective, cognitive, and cardiovascular effects of 2C-B (20 mg) in comparison to psilocybin (15mg) and placebo in a within-subjects, double-blind, placebo-controlled study of 22 healthy psychedelic-experienced participants. 2C-B elicited alterations of waking consciousness of a psychedelic nature, with dysphoria, subjective impairment, auditory alterations, and affective elements of ego dissolution largest under psilocybin. Participants demonstrated equivalent psychomotor slowing and spatial memory impairments under either compound compared to placebo, as indexed by the Digit Symbol Substitution Test (DSST), Tower of London (TOL) and Spatial Memory Task (SMT). Neither compound produced empathogenic effects on the Multifaceted Empathy Test (MET). 2C-B induced transient pressor effects to a similar degree as psilocybin. The duration of self-reported effects of 2C-B was shorter than that of psilocybin, largely resolving within 6 hours. Present findings support the categorisation of 2C-B as a subjectively "lighter" psychedelic. Tailored dose-effect studies are needed to discern the pharmacokinetic dependency of 2C-B's experiential overlaps.

## Keywords:

# Introduction

Classical psychedelics are a diverse set of psychoactive compounds characterised by their capacity to elicit profound alterations in waking consciousness, comprising changes to mood, cognition, and self-referential awareness[1]. Promising evidence that compounds such as psilocybin are safe and efficacious treatments for neuropsychiatric disorders such as major depressive disorder (MDD) has fostered a renewed interest in their effects[2-4].

Like other psychedelics (e.g. *d*-lysergic acid - LSD, mescaline, and *N,N*-dimethyltryptamine - DMT), the effects of psilocin (the active metabolite of psilocybin) are understood to be primarily mediated via partial serotonin (5-HT) receptor agonism, predominantly the $5\text{-HT}_{2A}$ receptor as well as $5\text{-HT}_{1A}$ and $5\text{-HT}_{2C}$ receptors [5,6]. Extensive human behavioural studies have characterised the acute subjective, cognitive, and autonomic effects of psilocybin [7-13], making it a valuable candidate for clinical use.

While significant emphasis has been placed on the central role of $5\text{-HT}_{2A}$ receptor agonism in mediating alterations to waking consciousness [14], classical psychedelics are suggested to hold subtly distinct pharmacodynamics. Indoleaklymaines such as the ergoline LSD or the tryptamines psilocybin and DMT exhibit varying receptor binding selectivity and potency particularly in comparison to phenethylamines such as mescaline, likely as a function of their structural (as)similarity [15,16]. Evidence has begun to emerge suggesting experiential differences may not only be explained by functional selectivity at the $5\text{-HT}_{2A}$ receptor but in contrast, orchestrated by an entourage of receptor subclasses [17,18].

With the advent of modern biochemistry, novel compounds distinct from their classical progenitors have readily appeared. Of these is the psychedelic entactogen 2,5-dimethoxy-4-bromophenethylamine (2C-B), a first-generation synthetic analogue of mescaline isolated and publicised by Alexander Shulgin in 1974[19]. Belonging to the 2C-series of 2,4,5 trisubstituted phenethylamines, members share core methoxy functional groups at carbons 2 and 5 ,but differ in ligands at the fourth position on the phenyl ring, e.g., bromine in 2C-B or propyl in 2C-P [20]. Manifold increases in receptor efficacy and potency with respect to mescaline have been observed following such alterations in ligand positioning [21]. 2C-B shows high $5\text{-HT}_{2A}/5\text{-HT}_{2C}$ receptor selectivity and has been demonstrated to reliably elicit head twitch responses in rodents, a behavioural proxy of $5\text{-HT}_{2A}$ agonism [22-25]. In recent years, research has indicated secondary affinity at $5\text{-HT}_{2B}$, $5\text{-HT}_{1A}$, dopamine $D_{1/2/3}$, adrenergic $\alpha_{1/2}$, histamine $H_1$ and $TAAR_1$ receptors[21]. Notably,

3

2C-B shows parallels with 3,4-methylenedioxymethamphetamine (MDMA) due to (albeit weaker) reuptake inhibition of the serotonin reuptake transporter (SERT) and, to a lesser extent, norepinephrine (NET) and dopamine reuptake transporters (DAT) [26,27], likely supplemented by monoamine oxidase ($MAO_{A/B}$) inhibition [28,29].

To date, 2C-B is the most frequently used novel psychedelic among recreational drug users [30,31] and serves as a structural reference point for the development of novel compounds [32]. Despite its prevalence, little is known regarding its effect profile in humans, making it difficult to ascertain any potential risks or clinical merits. A body of survey data and anecdotal reports highlight mild psychedelic effects typical of serotonergic hallucinogens, paired with feelings of euphoria and emotional openness akin to the entactogen MDMA[33,34]. Whereas naturalistic observational studies have begun to corroborate these reports and expanded on the relative safety of 2C-B [35,36], a complete neuropsychopharmacological assessment of its acute effects under double-blind conditions has yet to be performed.

The present study therefore sought to describe and compare the subjective, cognitive, and cardiovascular effects of 2C-B (20 mg) vs psilocybin (15 mg) psilocybin in healthy volunteers. Comparative studies employing a within-subjective design offer the opportunity to directly assess commonalities between substances across a range of standardised measures. Moreover, by including different compounds of comparable phenomenology and effect duration, it may also be possible to minimise expectancy effects clouding subjective responses to psychedelics [37]. Considering prior findings of entactogenic qualities, we hypothesised 2C-B would produce distinct subjective emotional effects compared to psilocybin.

# Materials and methods

The study employed a double-blind, placebo-controlled, crossover design with three acute experimental sessions to investigate responses to placebo, 2C-B, and psilocybin. Participants were randomly allocated to intervention orders following Latin-square counterbalancing. Each acute session was separated by a 14-day washout. The study (trial register NL8813) was conducted according to the Declaration of Helsinki (1964) and amended in Fortaleza (Brazil, October 2013) and in accordance with the Medical Research Involving Human Subjects Act (WMO) and was approved (NL73539.068.20) by the Academic Hospital and University's Medical Ethics committee of Maastricht University.

## Participants

Twenty-two healthy participants (11 female) aged 19-35 years (mean ± SD: 25 ± 4 years) were recruited by word of mouth and advertisement shared via Maastricht University social media platforms.

The inclusion criteria were: 18-40 years of age; previous experience with a psychedelic drug but not within the past 3 months; body mass index between 18 and 28 kg/m2; free from medication (any drug prescribed for a medical indication); good physical health, including absence of major medical, endocrine, and neurological conditions; and written informed consent. The exclusion criteria included history of drug abuse or addiction, pregnancy, or lactation, current or history of psychiatric disorders, absence of reliable contraceptives, previous experience of serious side effects to psychedelics, and MRI contraindications. Before inclusion, participants were screened and examined by an independent study physician, who checked for general health, conducted a resting ECG, and took blood and urine samples in which haematology, clinical chemistry and urine analyses were conducted.

All participants were fully informed of all procedures, possible adverse reactions, legal rights, and responsibilities, expected benefits, and their right to voluntary termination without consequences. All participants provided their informed consent, in writing, prior to their inclusion in the study and are to be remunerated for their participation. An overview of the recruitment process, CONSORT flowchart and complete demographic data can be found in the supplementary materials.

## Study drugs

Each intervention was administered orally, in a closed cup either containing placebo (inactive; bittering agent) or bittering agent and psilocybin/2C-B (powder). Blinding integrity was assessed retrospectively at the end of each acute experimental visit. A permit for obtaining, storing, and administering 2C-B and psilocybin was obtained from the Dutch Drug Enforcement Administration. The choice of dose and drug was determined by the requirement to generate substantial, yet tolerable, altered state of consciousness in the absence of existing 5-HT$_{2A}$ receptor occupancy data for 2C-B. Prior work has indicated the tolerability, safety and comparable onset times of moderate dose of 20 mg 2C-B [36,38] and 15mg psilocybin [9,39].

## Study procedures

Upon enrolment, and prior to the start of testing cycles, participants were invited to a preparatory training visit where they met and built rapport with the experimenters and were trained on all computerised tasks and procedures.

Each acute experimental session lasted approximately 7 hours. On the morning of the dosing day, participants were instructed to have a light breakfast at home. Participants were reminded to refrain from drug use, including psychedelic drugs (≥ 3 months), alcohol (≥24 hours), and all other drugs of abuse (≥7 days) before each experimental visit. Additionally, participants were asked to refrain from caffeine and nicotine use on each test day. All psychoactive drug use was prohibited throughout the duration of the study (7 weeks). On arrival of a test day, absence of drug and alcohol use was assessed via a urine drug screen and a breath alcohol screen. A pregnancy test was given to females. If all tests were found to be negative, a venous catheter was placed, and participants were allowed to proceed with administration. The acute experimental sessions were conducted in a quiet psychopharmacology lab. In between testing, the participants could interact with the investigator, rest, read, or listen to music via headphones. Participants stayed under supervision until the testing day was complete and the experimenters deemed they were fit to go home.

## Subjective effects

Detailed descriptions of all inventories are provided in the supplementary materials.

Subjective effects were assessed repeatedly using visual analogue scales (VAS) at baseline (0h), +0.5, +1, +1.5, +2, +3, +4, +5, +6 hours after administration. These scales included "*any drug effect*," "*good drug effect*", "*bad drug effect*", "*drug liking*," "*drug high*"," "*happy*"," *concentration*", "*creative*", "*productive*" ,"*sociable*" marked from "not at all" (0) to "extremely" (100) and "*sense of time*" marked from "slow" (0) to "fast" (100) [40,41].

Hourly measures (0, +1, + 2, +3, +4, +5, +6h) were taken for a broader characterisation of present-state effects. Changes in mood were assessed using the 65-item Profile of Mood States (POMS) scale [42]. Levels of dissociative symptomatology were examined using the 19-item Clinician-Administered Dissociative States (CADSS) Scale [43]. Acute psychedelic effects were characterised using the 13-item Bowdle Visual Analogue (BVAS) Scale [44]. Lastly, current and general levels of drug liking and wanting were assessed using the 4-item Sensitivity to Drug Reinforcement Questionnaire (SDRQ)[45].

Furthermore, participants were asked to complete retrospective measures at the end of each test day. Alterations in waking consciousness were assessed using the 94-item 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) [46] and the Hallucinogen Rating Scale (HRS) [47]. In addition, levels of subjective ego-dissolution as defined by the 8-item Ego Dissolution inventory (EDI) [48] and end of session changes in trait empathy as per the 28-item Interpersonal Reactivity Index (IRI) [49] were examined.

## Cognitive tasks

A computer-based task battery was implemented during peak subjective effects to determine the differential impact of psilocybin and 2C-B on domains of cognition: Motor Control Task (MCT, sensorimotor coordination)[50], Psychomotor Vigilance Task (PVT, sustained attention)[51], Digit Symbol Substitution Test (DSST, overall cognitive impairment)[52], Tower of London (executive functioning)[53], the immediate and delayed (+30 min), Spatial Memory Test (SMT, spatial memory)[54], the Matching Familiar Figures Test (reflection impulsivity)[55] and the Multifaceted Empathy Test (MET, cognitive and emotional empathy )[56]. Parallel versions of the DSST, TOL, SMT and MFFT were provided for each dosing day. Participants were refamiliarised with all instructions prior to each task. All tasks and corresponding outcome measures are described in detail in the supplementary methods, with times of administration outlined in the upper panels of Fig.4.

## Cardiovascular effects

Blood pressure and heart rate were assessed hourly (0, +1, + 2, +3, +4, +5, +6h) with an arm blood pressure cuff (M6 Comfort Model HEM-7360-E, Omron-Healthcare, Kyoto Japan). For each timepoint, rate pressure product (systolic blood pressure * heart rate) was calculated as a measure of hemodynamic workload [57].

## Pharmacokinetic assessments

Venous blood samples were taken hourly (0, +1, + 2, +3, +4, +5, +6h) to assess levels of serum psilocin and 2C-B (ng/mL) using liquid chromatography-tandem mass spectrometry liquid chromatography-tandem mass spectrometry (LC-MS/MS; Agilent, Waldbronn, Germany, see supplementary materials).

## Statistics

We firstly determined peak changes from baseline for all repeated measurements peak effects ($\Delta E_{max}$ and/or $\Delta E_{min}$). Baseline-adjusted $E_{max}$ scores were calculated for all cardiovascular measures to assess clinically significant changes. All scores and task outcomes were incorporated into Linear Mixed Models (LMMs) with drug condition as a main fixed effect and participant as a random intercept to account for the dependency between repeated measures. A first-order autoregressive covariance structure (AR1) was used. If a significant main effect of drug condition was observed, estimated marginal means were compared between drug conditions. Tukey's method was used to correct for multiple comparisons in all analyses.

Prior to pharmacokinetic analyses, incomplete time courses were interpolated using multiple imputation chain equations (MICE), derived from the mice (version 3.15.0) package[58], following no detection of deviation from missing completely at random (MCAR) based on Little's MCAR test. Preliminary serum area under the curve (AUC) and half-lives were extrapolated using the NonCompart (version 0.6.0) package[59]. All pharmacokinetic analyses were performed in a non-compartmental fashion. The duration of acute subjective effects was estimated using the VAS "*any drug effect*" and extrapolating an on/off cut-off of 10% of the maximum individual response.

Statistical models were estimated using the *lme* function of the nlme (version 3.1.162) and the ImerTest (version 3.1.3) library [60,61] within the R environment [62] (version 4.2.1). For all analyses, the alpha criterion was set at $p < 0.05$. Information pertaining to missing data and study power calculation are outlined in the supplementary materials. All statistics are summarised in Table 1 and Table S1-3, with all pairwise comparisons supplied in Table S4. Measures subject to a main effect of drug condition are reported in text.

# Results

All 22 participants completed each condition of the study. Both 2C-B and psilocybin were well tolerated, with no serious adverse events arising throughout the course of the study.

[Table 1]

## Subjective effects

Subjective effect VAS over time is shown in Fig.1a. Statistics are summarised in Table 1 and Table S4. Overall, 2C-B and psilocybin generated significant yet equivalent increases in scores across most measures of subjective drug intensity (any drug effect, good drug effect, drug liking, drug high) in comparison to placebo. 2C-B produced significant elevations in bad drug effect compared to placebo, but not psilocybin. Subjective effects abated in under 6 hours for 86.3 % of participants under 2C-B vs 63.6 % under psilocybin (Fig.1b, see supplementary for additional details).

[Figure 1]

VAS pertaining to mood and time perception revealed further similarities. Both drugs significantly increased ratings of happiness and creativity in comparison to placebo with no differences arising between the two. Similarly, 2C-B and psilocybin equally induced greater mean reductions over time for self-reported sociability. Maximal reductions in concentration were significantly greater for psilocybin compared with placebo but not 2C-B. 2C-B and psilocybin similarly induced greater slowing of time perception in comparison to placebo, whereas increases in speed of time were significantly greater for psilocybin in comparison to 2C-B and placebo.

Multidimensional measures of mood, drug effects, and drug liking were taken hourly (see Fig.2, Table 1 and Table S4). Mood as assessed by the POMS (Fig.2a) revealed a greater degree of emotional liability under psilocybin. Psilocybin significantly increased levels across all negative mood subscales (total mood disturbance, tense, anger, fatigue, depression, confusion) compared with placebo. Of these, levels of depression were also significantly greater for psilocybin than 2C-B. Conversely, 2C-B solely elicited significant increases for the tense and confusion subscales in comparison with placebo. 2C-B produced significant increases in markers of positive affect (vigour, elation, friendliness) compared to placebo with the elevations in summary scale positive mood of larger magnitude than under psilocybin. Both compounds generated comparable significant increases on SDRQ scales of current and general drug liking and drug wanting compared to placebo.

9

[Figure 2]

Altogether, neither substance significantly differed from one another on any multidimensional measures of acute drug effects. Subjective ratings of dissociation (Fig.2b) and their corresponding subfactors (depersonalisation, derealisation, amnesia) as assessed by the CADSS were significantly greater under both drugs than placebo. Of the subscales, feelings of derealisation exhibited the largest magnitude of change under both drugs. Similarly, real-time scores of internal perception and external perception and high as per the BVAS (Fig.2c) were significantly greater for both substances compared to placebo.

Figure 3 shows participant ratings on three retrospective questionnaires completed approximately 6 hours after drug administration. Statistics are summarised in tables S1 and S4. These results generally show significant increases in measures assessing alterations to waking consciousness after 2C-B and psilocybin. On the 5D-ASC, 2C-B elicited a total alteration in waking consciousness of lesser magnitude in comparison to psilocybin (Fig.3a).

[Figure 3]

2C-B generated significantly greater effects for most scales in comparison to placebo, other than for auditory alterations, spiritual experience, and disembodiment. Psilocybin produced significant increases in all dimensions of the 5D-ASC in comparison to placebo. Particularly, psilocybin produced significantly greater increases in the scales oceanic boundlessness (OBE), anxious ego dissolution (AED), auditory alterations (AA), vigilance reduction (VIR), changed meaning of precepts and impaired control and cognition than 2C-B. Both produced significantly greater effects than placebo on the EDI and did not significantly differ from one another (Fig.3a). On the HRS, 2C-B and psilocybin produced significant increases in 4/5 dimensions other than volition (Fig.3b). Notably, psilocybin produced significantly greater increases on the affect and cognition scales than 2C-B. Neither substance significantly differed on the intensity scale of the HRS. Lastly, neither compound elicited any clear immediate changes to trait empathy relative to placebo as indexed by the IRI (Fig.3c).

## Neuropsychological task battery

Altogether, on all cognitive outcome measures, 2C-B and psilocybin comparable effects (see Fig. 4, Table S2, S4). Both produced significant impairments in global cognitive function when compared to placebo as indicated by a reduced number of correct responses and attempts on the DSST. However, no significant effect on general accuracy was identified.

[Figure 4]

Regarding local facets of cognition, both drugs relative to placebo were associated with significantly diminished scores in immediate and delayed SMT recall. Analyses revealed sensorimotor coordination, mental planning, reflection impulsivity, and empathy (cognitive and emotional) were unaltered under 2C-B and psilocybin, as indicated by the absence of a main effect of drug condition for the MST, PVT, TOL, MFFT and MET (+270 min, see supplementary) respectively. Delayed reaction times in comparison to placebo were selectively present for the DSST and TOL for both drugs as well as the PVT for psilocybin.

## Cardiovascular effects

Acute effects on vital signs over time are shown in Fig. 5a, with peak maximums shown in Table 1. For both compounds, significant pressor effects (systolic and diastolic) were observed in comparison to placebo. Systolic hypertension (>140 mmHg) was observed under 2C-B (n=5), psilocybin (n=8), and placebo (n=2), respectively. Tachycardia (>100 BPM) was observed under 2C-B (n=2) and placebo (n=2) respectively. However, despite a main effect of drug, no clear significant differences in heart rate were observed. Whereas 2C-B produced a significantly greater rate pressure product in comparison to placebo, this did not significantly differ between our active conditions, suggesting an overall similar myocardial output.

[Figure 5]

## Pharmacokinetics

Concentration time-curves can be found in Fig.5b. The maximum mean values (range, n) for 2C-B and psilocin serum concentrations ($C_{max}$) were 3.31 (1.63–7.58, n=21) and 10.81 (5.26–25.47, n=21) ng/mL, respectively and concordant with applied oral doses[10,35,63]. Maximum serum concentrations peaked for 2C-B on average at 2.43 h (1–4, n=21) vs 3.71 h (2–5, n=21) for psilocin. Mean $AUC_{0-6h}$ values were 9.43 h*ng/mL (5.03 -16.7, n=21) for 2C-B and 33 h*ng/mL (21.7 - 71.6, n=21) for psilocin. Available mean corresponding half-lives were 1.43 h (1.02 - 2.46, n=17) and 2.24 h (1.44 - 3.81, n=7) for 2C-B and psilocybin respectively. For either drug, exploratory Spearman rank correlations

11

did not reveal significant relationships between $C_{max}$, age, sex nor weight (see supplementary).

## Blinding

Following the completion of each test day, subjects were asked to retrospectively identify the intervention in question. Placebo was correctly identified by 95.5% of subjects, with 2C-B and psilocybin correctly identified by 63.6% of participants. 2C-B was misidentified as psilocybin by 36.4% of subjects. Psilocybin was misclassified as 2C-B for 31.8% of subjects and placebo for 4.5% of subjects (n=1). Data pertaining to blinding identification and decision confidence are shown in in the matrix S3.

# Discussion

The results presented herein provide the first clinical assessment and within-subject comparison of 2C-B and psilocybin across acute markers of subjective, cognitive, and cardiovascular effects in a placebo-controlled fashion. Our results indicate fixed doses of 20 mg 2C-B and 15 mg psilocybin produce broadly similar increases in all acute ratings of peak drug effect intensity, comparable with prior dose-effect studies[9,35], reflecting a psychotropic equivalence. These findings indicate 2C-B elicits alterations in waking consciousness of lesser experiential depth than psilocybin yet produces comparable cognitive impairment and cardiovascular stimulation.

Globally, 2C-B produced a range of subjective effects consistent with classical psychedelics [64]. Acute elevations in feelings of dissociation, perceptual change, creativity, and alterations to time perception were observed for both 2C-B and psilocybin. In contrast, nuanced differences in phenomenology were observed across retrospective measurements. Whereas 2C-B was found to elicit significant elevations across most scales outside of auditory alterations, disembodiment, and spiritual experience, the overall intensity of the experience was markedly lesser than that of psilocybin. While exhibiting equivalent alterations to visual (e.g., perception, VR) and bodily perception (ego dissolution, somaesthesia, internal perception), participants under the influence of psilocybin reported a greater propensity for affective qualities of altered self-experience (eg. OBE, AED) as well as impairment (e.g., VIR, impaired control and cognition, cognition). Taken together, these findings support descriptions of 2C-B being non-ego-threatening in nature, lacking the otherwise more serious headspace of classical precursors while imparting a greater emphasis on visual and tactile domains [19,34]. Consistent with this notion, classification of 2C-B's 5D-ASC profile in relation to other novel indoleaklylamines has indicated the profoundness of experience as an explanatory factor [31]. Subtle pharmacodynamic differences between psilocybin and 2C-B may

12

ultimately arise due to differing binding-profiles, given both the autoinhibitory and potentiating interplay of $5\text{-}HT_{1A}/5\text{-}HT_{2C}$ receptor subtypes on $5\text{-}HT_{2A}$-mediated behavioural responses [65-68] or the association of extraneous neuromodulatory systems with feelings of disembodiment and subjective impairment [69]. Alternatively, it can be suggested the brunt of experiential dissimilarities may instead lie in differing pharmacokinetics such as duration or dosage, given that both 2C-B and psilocybin were unmasked marginally above chance by participants (63.6% of cases). Previous drug-discrimination assays have previously shown a full substitution of most first-generation 2C-X compounds with LSD or DOI [70] as well as poor discriminability between psilocybin and LSD in previous comparative studies [9].

Whereas classical psychedelics and entactogens partly overlap in regards to their capacity to elicit a positive affective bias [40], the former may hold a greater propensity to induce dysphoric reactions due to greater emotional lability. As per prior work[9,35,36,71], significant elevations in measures pertaining to euphoria (e.g., drug liking, drug high, good drug effect) and friendliness for both 2C-B and psilocybin in comparison to placebo were identified. However, subjects under psilocybin also showed sustained mood disturbance compared to placebo, with significantly larger increases in depression and overall greater emotional range (affect) than 2C-B. Furthermore, compared to placebo, 2C-B did not demonstrate significant elevations in most acute POMS markers of negative affect (anger, fatigue, depression) instead producing elevations in vigour, elation, and positive mood in a similar manner to MDMA [72]. Seconding this, 2C-B's effects have been described to resemble a "candy flip," the concurrent use of MDMA and LSD [34]. By nature of their action as monoamine reuptake inhibitors, entactogens and psychostimulants are likely to confer lesser susceptibility to negative mood states. For example, noradrenergic effects appear important for their euphoriant nature [73,74] while DAT/SERT selectivity has been suggested to distinguish amphetamine-like stimulants from entactogens [75,76]. In this regard, MDMA and 2C-B have been shown to hold similar DAT/SERT inhibition ratios of 0.08 while stimulants such as amphetamine or methamphetamine show values greater than 10 [21,77]. Pharmacological challenge studies using duloxetine (a SERT/NET reuptake inhibitor) and reboxetine (a NET reuptake inhibitor) seemingly abolish most mood-enhancing effects of MDMA [74,78].

Overall, 2C-B and psilocybin produced a similar profile of cognitive impairment. For the DSST, both compounds yielded reductions in the number of attempted and correct responses, with expectedly longer reaction times. However, neither substance exerted a significant effect on accuracy. Our observations are wholly congruent with work finding psilocybin dose-dependently reduces trial attempts yet spares global accuracy[79]. While

we agree with Barrett et al's 2018 interpretation that the absence of decrements in accuracy is unlikely to be indicative of global executive impairment, we propose parallel reductions in trial attempts and reaction time are another reflection of local impairment. Compensatory psychomotor slowing under high intrinsic cognitive load is likely indicative of deficits in information processing speed rather than a volitional shift in performance strategy[80] prioritising accuracy over speed. There is also good evidence to suggest disruptions to temporal processing and sensorimotor gating are mediated by 5-HT$_{2A}$ agonism [81-84]. Deficits in information processing may also consequently explain worsened TOL reaction times in the absence of any main effect on planning. General assessments of executive function such as the DSST are often reliant on a combination of latent cognitive processes such as good motor coordination, spatial memory, sustained attention and response inhibition all of which may be differentially affected according to dose or agent in question [52]. For example, motor coordination under psilocybin was only previously shown to be affected under high doses (20mg and beyond)[79]. We also observed significant impairments to both short and long-term spatial memory under each compound despite previous evidence of this across serotonergic hallucinogens being mixed [54,85-87]. Furthermore, any attentional deficits induced by primary 5-HT$_{2A}$ agonists are likely selective: studies employing psilocybin in combination with ketanserin (a 5-HT$_{2A/2C}$ antagonist) have specified declines in attentional tracking ability on paradigms requiring distractor inhibition [85], suggesting an enhanced salience of distractor stimuli under rather than reduced sustained attentional capacity per se. While disruptions in inhibitory motor responding are seemingly a core feature of serotonergic hallucinogens [72,84,88], no effect on MFFT performance was identified, reflecting an unaffected impulsive choice capacity[89]. Similarly, no empathogenic qualities were identified on the MET for either drug, notwithstanding elevations in emotional empathy being cited for similar doses of psilocybin and MDMA [90]. With both tasks administered at the tail-end of effect intensity, any absence of effect may be a function of time. Going forwards, homing in on clinically relevant domains of cognition will specify our findings further. With alterations in cognitive flexibility being cited as an integral marker of the therapeutic effects of classical psychedelics [91], more expansive assessments of executive function such as set-shifting paradigms - may highlight novel differences [92-94].

Analogous elevations in blood pressure were identified under 2C-B and psilocybin in comparison to placebo. These were modest in nature and consistent with earlier trials employing classical psychedelics or 2C-B[8,9,35,40]. Magnitudes of change were also appreciably lesser than those observed following the administration of MDMA and related amphetamines [40,95,96]. Whereas no differences in HR were observed for 15 mg psilocybin as previously described for similar doses [9,39,97,98], we did not replicate the prior finding of elevated HR under 2C-B [35], likely as a result of differing subject inclusion criteria. These

preliminary findings therefore cautiously indicate that the 15 mg psilocybin and 20 mg 2C-B hold similar cardiovascular effects. However, it should be stressed that assessing the full range of 2C-B's autonomic and endocrine (e.g., cortisol) effects in future phase I trials may be more fruitful for assessing the tolerability of 2C-B.

The kinetics of 2C-B were largely dissociable from those of psilocin. Whereas both compounds demonstrated comparable onset of action times, the effects of 2C-B were shorter than those of psilocybin, mostly abating within 6 hours. This was mirrored by a shorter half -life and smaller AUC for 2C-B in comparison to psilocybin. These findings of low bioavailability may be in agreement with preclinical work suggesting that 2C-B undergoes an extensive first-pass effect after oral administration [27,99-101]. Body weight had no influence on 2C-B or psilocin serum concentrations, Thus, unlike MDMA[102] administering 2C-B as a fixed dose may confer equivalent advantages to weight-adjusted dosing similarly to other classical psychedelics [103].

Limitations inherent to the study design warrant consideration. Firstly, single doses were used. For a complete categorisation of 2C-B, future trials (eg: NCT05523401) employing an escalating dosing regimen with both MDMA and psilocybin as comparators of interest may provide applicable dosing ranges for healthy subjects. Furthermore, all neurocognitive tasks were performed at fixed timepoints as to accommodate a battery of sufficient breadth. With psychoactive effects being experienced-timeline dependent, differences in actual versus perceived impairment may be reliant on pharmacokinetic differences. However, most tasks were administered at times of approximate peak subjective effects, maintained across the 2 and 4-hour timepoints for both compounds. It is therefore likely tasks administered at these timeframes were not compromised by differences in task timing relative to effect intensity ratings. The present study also had a primary focus on the immediate effects of each compound and by design, did not extend pharmacokinetic sampling beyond 6 hours. Given the subjective effects of psilocybin were not self-resolving by 6h, future studies spanning a full, predefined sampling interval[104] may more accurately extrapolate population pharmacokinetic parameters such as half-life, clearance or $IC_{50}$. Lastly, testing was performed in a controlled environment, enrolling a homogeneous sample of experienced volunteers. Thus, subjects in different settings, pertaining to different backgrounds may respond in unseen ways to 2C-B or psilocybin. For example, variations have been noted in how individuals perform on the TOL under ayahuasca based on prior use history (where more experienced users show lesser impairment)[105].

Caveats aside, our findings highlight key considerations for clinical pathfinding. If shown to produce positive mood sequelae akin to classical precursors, novel analogues such as 2C-B which might elicit a mentally "clearer" subjective state, are likely scalable to implement at a clinic, given that acute contact time and dysphoria can be lessened [106]. For example, evidence of a lessened predisposition to adverse psychological effects may make 2C-B a useful means by which patients apprehensive of macrodoses or at risk of adverse reactions (e.g, high neuroticism) [107,108] can be familiarised with a psychedelic-induced subjective experience within a therapeutic model, while retaining resemblances to classical psychedelics in its capacity to induce ego dissolution. Accordingly, dosages of 15-30mg 2C-B have been reportedly employed in both individual and group psycholytic psychotherapy, often adjunct to MDMA or LSD [109].

### Conclusion

In summary, these findings give new impetus to the categorisation of 2C-B as a psychedelic with some entactogenic properties. Producing a spectrum of acute subjective, cognitive, and pressor effects compatible with a primary 5-HT$_{2A}$ mode of action, 2C-B produces an effect profile of an intermediary experiential depth. Subsequently assessing it's acute effects on brain functional organisation, emotional processing and persisting effects will be valuable for understanding its relative harms and clinical utility.

# Funding and disclosure

# Author contributions

P.M designed and performed the research, analysed the data, and wrote the first version of the manuscript. N.M designed and performed the research and contributed to the manuscript review. J.R. supported data collection. R.P provided medical supervision and screening. S.T, S.R performed the serum concentration determinations. E.T, K.K

designed the research and contributed to the manuscript review. J.G.R designed the research, contributed to the manuscript review and acquired funding.

## Acknowledgments

## Table 1. Comparison of the acute effects of 2C-B, psilocybin and placebo

| | | Placebo (mean ± SEM) | 2C-B (mean ± SEM) | Psilocybin (mean ± SEM) | $F_{2,42}$ | p-value |
|---|---|---|---|---|---|---|
| **Subjective effects VAS (% max)** | | | | | | |
| Any drug effect | $\Delta E$max | 8.35 ± 3.05 | 75.45±4.65*** | 76.23±4.24*** | 81.05 | < 0.001 |
| Good drug effect | $\Delta E$max | 12.55 ± 4.59 | 69.45±4.82*** | 76.55±5.4*** | 57.36 | < 0.001 |
| Bad drug effect | $\Delta E$max | 7.45 ± 3.31 | 23.29±4.37* | 20.82±5.74 | 3.34 | 0.045 |
| Drug liking | $\Delta E$max | 12.8 ± 5.55 | 66.64±5.04*** | 73.18±4.67*** | 64.15 | < 0.001 |
| Drug high | $\Delta E$max | 6.8 ± 2.98 | 74.41±5.53*** | 82.55±3.77*** | 87.01 | < 0.001 |
| Happy | $\Delta E$max | 10.96 ± 3.46 | 24.55±4.64* | 23.86±4.33* | 4.59 | 0.016 |
| | $\Delta E$min | -11.77 ± 3.06 | -15.92 ± 4.12 | -21.36 ± 4.32 | 1.81 | 0.176 |
| Concentration | $\Delta E$max | 9.6 ± 3.45 | 14.41 ± 3.77 | 9.59 ± 2.39 | 1 | 0.378 |
| | $\Delta E$min | -19.3 ± 3.61 | -30.82±3.91 | -36.27±5.1* | 3.3 | 0.047 |
| Creative | $\Delta E$max | 7.82 ± 2.18 | 25.36±4.13** | 22.55±3.98* | 6.68 | 0.003 |
| | $\Delta E$min | -15.39 ± 3.12 | -19.39 ± 3.87 | -19.48 ± 2.82 | 0.52 | 0.601 |
| Productive | $\Delta E$max | 10.37 ± 3.62 | 13.91 ± 3.22 | 14.73 ± 3.2 | 0.4 | 0.672 |
| | $\Delta E$min | -21.25 ± 4.39 | -29.66 ± 4 | -33.09 ± 3.39 | 2.76 | 0.075 |
| Sociable | $\Delta E$max | 14.84 ± 4.02 | 22.69 ± 4.81 | 20.35 ± 3.07 | 1.43 | 0.25 |
| | $\Delta E$min | -14.27 ± 3.19 | -25.23±3.69* | -24.85±4.17* | 4.95 | 0.012 |
| Sense of time | $\Delta E$max | 2.29 ± 0.51 | 9.05±2.76 | 17.99±3.56***# | 9.85 | < 0.001 |
| | $\Delta E$min | -7.87 ± 2.28 | -20.51±3.98* | -23.93±4** | 5.06 | 0.011 |
| **Profile of Moods State (POMS) score** | | | | | | |
| Total mood disturbance | $\Delta E$max | 5.95 ± 1.16 | 15.45±2.69 | 23.23±4.81*** | 9.58 | < 0.001 |
| Tense | $\Delta E$max | 0.77 ± 0.19 | 4.77±1.08** | 4.27±0.87* | 6.61 | 0.003 |
| Anger | $\Delta E$max | 0.41 ± 0.18 | 1.41±0.34 | 2.05±0.67* | 4.32 | 0.02 |
| Fatigue | $\Delta E$max | 1.91 ± 0.54 | 3.23±0.62 | 4.41±0.93* | 4.19 | 0.022 |
| Depression | $\Delta E$max | 0.32 ± 0.14 | 1.59±0.38 | 4.82±1.35***# | 9.29 | < 0.001 |
| Confusion | $\Delta E$max | 1.68 ± 0.3 | 6.05±0.77*** | 7.77±0.82*** | 30.38 | < 0.001 |
| Positive mood | $\Delta E$max | 1.73 ± 0.51 | 6.14±1.23** | 3.59±0.66# | 7.89 | 0.001 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | Arousal | ΔEmax | 1.32 ± 0.49 | 4.86 ± 1.48 | 3.41 ± 1.08 | 2.98 | 0.061 |
| | Vigour | ΔEmax | 1.36 ± 0.34 | 5±1.28* | 4±0.96 | 3.73 | 0.032 |
| | Elation | ΔEmax | 0.95 ± 0.3 | 5.68±1.24*** | 3.5±0.65 | 8.87 | 0.001 |
| | Friendliness | ΔEmax | 1.5 ± 0.55 | 4.41±0.81** | 4±0.68* | 7.01 | 0.002 |
| Clinician-Administered Dissociative States Scale (CADSS) score | | | | | | | |
| | Scale maximum | ΔEmax | 0.68 ± 0.38 | 22.36±3.09*** | 24.09±2.8*** | 26.63 | < 0.001 |
| | Amnesia | ΔEmax | 0.23 ± 0.13 | 3.14±0.42*** | 3.5±0.45*** | 26.49 | < 0.001 |
| | Depersonalisation | ΔEmax | 0.14 ± 0.1 | 4.64±0.89*** | 4.55±0.75*** | 12.79 | < 0.001 |
| | Derealisation | ΔEmax | 0.45 ± 0.23 | 15.32±2.08*** | 17.09±2.18*** | 25.13 | < 0.001 |
| Bowdle Visual Analog Scales (BVAS) score | | | | | | | < 0.001 |
| | Internal perception | ΔEmax | 0.06 ± 0.02 | 0.94±0.09*** | 1.03±0.1*** | 47.52 | < 0.001 |
| | External perception | ΔEmax | 0.05 ± 0.02 | 0.38±0.06** | 0.48±0.09*** | 12.69 | < 0.001 |
| | High | ΔEmax | 0.13 ± 0.06 | 1.44±0.07*** | 1.56±0.03*** | 190.46 | < 0.001 |
| Sensitivity to Drug Reinforcement Questionnaire (SCRQ) score | | | | | | | < 0.001 |
| | Current liking | ΔEmax | 0.41 ± 0.18 | 2.32±0.22*** | 2.91±0.22*** | 35.49 | < 0.001 |
| | Current wanting | ΔEmax | 0.41 ± 0.2 | 1.59±0.31*** | 1.91±0.25*** | 15.75 | < 0.001 |
| | General liking | ΔEmax | 0.36 ± 0.18 | 1.91±0.29*** | 2.27±0.32*** | 21.19 | < 0.001 |
| | General wanting | ΔEmax | 0.32 ± 0.2 | 1.55±0.3*** | 1.64±0.3*** | 14.32 | < 0.001 |
| Cardiovascular effects | | | | | | | < 0.001 |
| | Systolic blood pressure (mmHg) | Emax | 112.55 ± 2.11 | 118.91±2.54* | 121.64±2.45** | 7.46 | 0.002 |
| | Diastolic blood pressure (mmHg) | Emax | 68.64 ± 1.54 | 73.91±1.62* | 76.91±1.72*** | 11.8 | < 0.001 |
| | Heart rate (beats/min) | Emax | 70.55 ± 3.28 | 75±2.78 | 68.59±2.65## | 5.66 | 0.007 |
| | Rate-pressure product | Emax | 9207.36 ± 373.18 | 10317.64±372.38* | 9877.41±326.53 | 4.1 | 0.024 |

*P<0.05, **P<0.01, ***P<0.001 compared with placebo; #P<0.05, ##P<0.01, ###P<0.001 compared with 2C-B

# Figures



**Figure 1.** Subjective effects of 2C-B and psilocybin over time on VAS measurements of subjective effects. **(a)** Time courses of each VAS measurement. Data are presented as mean ± SEM (brackets). All values corresponding pairwise statistics are presented in tables 1 and S4. **(b)** Count plot of "Any effect" on/off duration. Absolute frequencies for each bin are depicted for each drug.

**Figure 2.** Effect of 2C-B and psilocybin over time on hourly multidimensional measurements of mood, dissociation, and psychedelic effects. Data points are shown as means ± SEM (brackets). Corresponding pairwise statistics for these findings

1

as well as additional subscales are presented in tables 1 and S4. **(a)** Time courses of all primary Profile of Mood States (POMS). **(b)** Time courses of each Clinician-Administered Dissociative States Scale (CADSS) dimension. **(c)** Time courses of the Bowdle Visual Analogue Scale (B-VAS), factors assessing high, changes to bodily and extraneous perception.

**Figure 3.** Effect of 2C-B and psilocybin on retrospective measures of changes to waking consciousness and trait empathy. All means ± SEM (brackets) as well as corresponding pairwise statistics are presented in S1 and S4. The presence of significant main drug effect is indicated as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. **(a)** Combined scores of the 5-Dimensions of Altered States Questionnaire (5D-ASC) alongside the Ego dissolution Inventory (EDI). **(b)** Participant ratings on the Hallucinogen Rating scale (HRS). **(c)** End-of-session differences in trait empathy on the interpersonal reactivity index (IRI).

**Figure 4.** Approximate time course and primary outcomes of task battery. The uppermost panel of each column depicts a schematic of each task as presented to participants with each corresponding time of administration relative to dosing. Lower panels display outcomes as a combined violin plot, boxplot, and mean line (±SEM). In the boxplot, the line dividing the box represents the median, the ends represent the upper 75th / lower 25th percentiles, and the extreme lines represent the full range. Significant pairwise comparisons following a main effect of drug are indicated as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. **(a)** Motor control task. A target is presented randomly on screen and must be selected as quickly as possible. Participant accuracy (Euclidean distance from target centre) 5) and response times (RTs) are recorded. **(b)** Tower of London. Participants must assess whether the end-arrangement (1>2) can be accomplished in 2-5 steps as quickly as possible. Response times and total correct responses are assessed. **(c)** Psychomotor vigilance task. Subjects must respond to a randomly appearing visual stimulus as quickly as possible. Total attentional lapses (RTs >500 ms) and RTs are

registered. **(d)** Digit symbol substitution test. Participants must quickly match novel inputs according to their corresponding digit-symbol combination within 90 seconds, with total correct responses and RTs being the primary outcomes. **(e)** Spatial memory test. Participant must memorise the location of a sequence of 10 targets and individually indicate their correct position (1/2). Subjects are queried 30 minutes later on their location. Total correct responses and RTs are measured. **(f)** Matching familiar figures task. Targets must be matched to one of six possible corresponding alternatives as quickly as possible. Trials are repeated in the presence of an error, with main outcomes being the total number of errors and RTs. All outcomes and corresponding pairwise statistics are presented in tables S2 and S4.

**Figure 5.** Cardiovascular and pharmacokinetic time-courses of 2C-B and psilocybin. **(a)** Cardiovascular effects over time. Data points are shown as means ± SEM (brackets) with statistical outcomes provided in tables 1 and S4. **(b)** Pharmacokinetic time courses for 2C-B and psilocin. Data points are shown as means ± SEM (brackets) in conjunction with a boxplot for which line dividing the box represents the median, the ends represent the upper 75th / lower 25th percentiles, and the extreme lines represent the full range. **(c)** Effect/concentration hysteresis plots. The pharmacodynamic values are

the mean values for any drug effect at each time point in 21 subjects. The time of sampling is noted next to each point (in hours after administration).

# References

1       Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. *Nature Reviews Neuroscience* **21**, 611-624 (2020).

2       Goodwin, G. M. *et al.* Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *New England Journal of Medicine* **387**, 1637-1648, doi:10.1056/NEJMoa2206443 (2022).

3       Davis, A. K. *et al.* Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry* **78**, 481-489, doi:10.1001/jamapsychiatry.2020.3285 (2021).

4       Carhart-Harris, R. *et al.* Trial of Psilocybin versus Escitalopram for Depression. *New England Journal of Medicine* **384**, 1402-1411, doi:10.1056/NEJMoa2032994 (2021).

5       Rickli, A., Moning, O. D., Hoener, M. C. & Liechti, M. E. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. *Eur Neuropsychopharmacol* **26**, 1327-1337, doi:10.1016/j.euroneuro.2016.05.001 (2016).

6       Madsen, M. K. *et al.* Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. *Neuropsychopharmacology* **44**, 1328-1334, doi:10.1038/s41386-019-0324-9 (2019).

7       Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. & Liechti, M. E. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. *Clinical Pharmacology & Therapeutics* (2022).

8       Hasler, F., Grimberg, U., Benz, M. A., Huber, T. & Vollenweider, F. X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-

blind, placebo-controlled dose–effect study. *Psychopharmacology* **172**, 145-156 (2004).

9       Holze, F. *et al.* Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacology* **47**, 1180-1187 (2022).

10      Brown, R. T. *et al.* Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. *Clinical Pharmacokinetics* **56**, 1543-1554, doi:10.1007/s40262-017-0540-6 (2017).

11      Griffiths, R. R. *et al.* Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology* **218**, 649-665 (2011).

12      Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology* **187**, 268-283 (2006).

13      Bălăeţ, M. Psychedelic Cognition-The Unreached Frontier of Psychedelic Science. *Front Neurosci* **16**, 832375, doi:10.3389/fnins.2022.832375 (2022).

14      Kim, K. *et al.* Structure of a Hallucinogen-Activated Gq-Coupled 5-HT(2A) Serotonin Receptor. *Cell* **182**, 1574-1588.e1519, doi:10.1016/j.cell.2020.08.024 (2020).

15      Kwan, A. C., Olson, D. E., Preller, K. H. & Roth, B. L. The neural basis of psychedelic action. *Nature Neuroscience* **25**, 1407-1419, doi:10.1038/s41593-022-01177-4 (2022).

16      McClure-Begley, T. D. & Roth, B. L. The promises and perils of psychedelic pharmacology for psychiatry. *Nature Reviews Drug Discovery* **21**, 463-473, doi:10.1038/s41573-022-00421-7 (2022).

17    Ballentine, G., Friedman, S. F. & Bzdok, D. Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences. *Science Advances* **8**, eabl6989, doi:doi:10.1126/sciadv.abl6989 (2022).

18    Zamberlan, F. *et al.* The varieties of the psychedelic experience: a preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. *Frontiers in integrative neuroscience* **12**, 54 (2018).

19    Shulgin, A. T. & Shulgin, A. *PIHKAL: a chemical love story*. Vol. 963009605 (Transform Press Berkeley, CA, 1991).

20    Dean, B. V., Stellpflug, S. J., Burnett, A. M. & Engebretsen, K. M. 2C or Not 2C: Phenethylamine Designer Drug Review. *Journal of Medical Toxicology* **9**, 172-178, doi:10.1007/s13181-013-0295-x (2013).

21    Rickli, A. *et al.* Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). *Neuropharmacology* **99**, 546-553, doi:https://doi.org/10.1016/j.neuropharm.2015.08.034 (2015).

22    Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J. & Brandt, S. D. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. *Neuropharmacology* **167**, 107933 (2020).

23    Marcher-Rørsted, E. *et al.* Investigation of the 2, 5-dimethoxy motif in phenethylamine serotonin 2A receptor agonists. *ACS Chemical Neuroscience* **11**, 1238-1244 (2020).

24    Halberstadt, A. L., Chatha, M., Stratford, A., Grill, M. & Brandt, S. D. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs. *Neuropharmacology* **144**, 368-376 (2019).

25    Luethi, D., Trachsel, D., Hoener, M. C. & Liechti, M. E. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). *Neuropharmacology* **134**, 141-148, doi:https://doi.org/10.1016/j.neuropharm.2017.07.012 (2018).

26    Zwartsen, A. *et al.* Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. *Toxicology in Vitro* **45**, 60-71, doi:https://doi.org/10.1016/j.tiv.2017.05.010 (2017).

27    Montgomery, T. *et al.* Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines. *Br J Pharmacol* **152**, 1121-1130, doi:10.1038/sj.bjp.0707473 (2007).

28    Wagmann, L., Brandt, S. D., Stratford, A., Maurer, H. H. & Meyer, M. R. Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. *Drug Testing and Analysis* **11**, 318-324, doi:https://doi.org/10.1002/dta.2494 (2019).

29    Páleníček, T. *et al.* Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. *Psychopharmacology* **225**, 75-93, doi:10.1007/s00213-012-2797-7 (2013).

30    Sexton, J. D., Nichols, C. D. & Hendricks, P. S. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. *Front Psychiatry* **10**, 896, doi:10.3389/fpsyt.2019.00896 (2019).

31    Mallaroni, P., Mason, N. L., Vinckenbosch, F. R. J. & Ramaekers, J. G. The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides. *Psychopharmacology* **239**, 1783-1796, doi:10.1007/s00213-022-06142-4 (2022).

4

32    Elliott, S. P., Holdbrook, T. & Brandt, S. D. Prodrugs of New Psychoactive Substances (NPS): A New Challenge. *Journal of Forensic Sciences* **65**, 913-920, doi:https://doi.org/10.1111/1556-4029.14268 (2020).

33    Caudevilla-Gálligo, F. *et al.* 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. *Journal of Psychopharmacology* **26**, 1026-1035, doi:10.1177/0269881111431752 (2012).

34    Palamar, J. J. & Acosta, P. A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines. *Human Psychopharmacology: Clinical and Experimental* **35**, e2719, doi:https://doi.org/10.1002/hup.2719 (2020).

35    Papaseit, E. *et al.* Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. *Front Pharmacol* **9**, 206, doi:10.3389/fphar.2018.00206 (2018).

36    González, D., Torrens, M. & Farré, M. Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. *Biomed Res Int* **2015**, 643878, doi:10.1155/2015/643878 (2015).

37    Aday, J. S. *et al.* Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. *Psychopharmacology* **239**, 1989-2010, doi:10.1007/s00213-022-06123-7 (2022).

38    Papaseit, E. *et al.* Acute Effects of 2C-E in Humans: An Observational Study. *Frontiers in Pharmacology* **11**, doi:10.3389/fphar.2020.00233 (2020).

39    Carbonaro, T. M., Johnson, M. W., Hurwitz, E. & Griffiths, R. R. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. *Psychopharmacology* **235**, 521-534, doi:10.1007/s00213-017-4769-4 (2018).

40    Holze, F. *et al.* Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. *Neuropsychopharmacology* **45**, 462-471 (2020).

41    Hutten, N. R. P. W. *et al.* Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. *European Neuropsychopharmacology* **41**, 81-91, doi:https://doi.org/10.1016/j.euroneuro.2020.10.002 (2020).

42    McNair, D. M., Lorr, M. & Droppleman, L. F. Manual profile of mood states. (1971).

43    Bremner, J. D. *et al.* Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). *J Trauma Stress* **11**, 125-136, doi:10.1023/a:1024465317902 (1998).

44    Bowdle, A. T. *et al.* Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. *The Journal of the American Society of Anesthesiologists* **88**, 82-88 (1998).

45    Kuypers, K. P. C. *et al.* Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine. *Psychopharmacology* **235**, 2349-2356, doi:10.1007/s00213-018-4931-7 (2018).

46    Studerus, E., Gamma, A. & Vollenweider, F. X. Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS One* **5**, e12412, doi:10.1371/journal.pone.0012412 (2010).

47    Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. & Kellner, R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. *Arch Gen Psychiatry* **51**, 98-108, doi:10.1001/archpsyc.1994.03950020022002 (1994).

48    Nour, M. M., Evans, L., Nutt, D. & Carhart-Harris, R. L. Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). *Frontiers in human neuroscience*, 269 (2016).

49      Davis, M. H. Interpersonal reactivity index.  (1980).

50      Sandberg, M. A. in *Encyclopedia of Clinical Neuropsychology*   (eds Jeffrey S. Kreutzer, John DeLuca, & Bruce Caplan)  480-482 (Springer New York, 2011).

51      Dinges, D. F. & Powell, J. W. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. *Behavior research methods, instruments, & computers* **17**, 652-655 (1985).

52      Jaeger, J. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing. *J Clin Psychopharmacol* **38**, 513-519, doi:10.1097/jcp.0000000000000941 (2018).

53      Kaller, C. P., Unterrainer, J. M. & Stahl, C. Assessing planning ability with the Tower of London task: psychometric properties of a structurally balanced problem set. *Psychological Assessment* **24**, 46 (2012).

54      Kuypers, K. P. C. & Ramaekers, J. G. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. *Psychopharmacology* **189**, 557-563, doi:10.1007/s00213-006-0321-7 (2007).

55      Viator, R. E., Wu, Y. J. & Viator, A. S. Testing the validity and reliability of the Matching Familiar Figures Test-2021: An updated behavioral measure of reflection-impulsivity. *Front Psychol* **13**, 977808, doi:10.3389/fpsyg.2022.977808 (2022).

56      Dziobek, I. *et al.* Dissociation of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted Empathy Test (MET). *J Autism Dev Disord* **38**, 464-473, doi:10.1007/s10803-007-0486-x (2008).

57      Gobel, F. L., Norstrom, L. A., Nelson, R. R., Jorgensen, C. R. & Wang, Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise

in patients with angina pectoris. *Circulation* **57**, 549-556, doi:10.1161/01.CIR.57.3.549 (1978).

58     van Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software* **45**, 1 - 67, doi:10.18637/jss.v045.i03 (2011).

59     Kim, H., Han, S., Cho, Y. S., Yoon, S. K. & Bae, K. S. Development of R packages: 'NonCompart' and 'ncar' for noncompartmental analysis (NCA). *Transl Clin Pharmacol* **26**, 10-15, doi:10.12793/tcp.2018.26.1.10 (2018).

60     Pinheiro, J. *et al.* Package 'nlme'. *Linear and nonlinear mixed effects models, version* **3**, 274 (2017).

61     Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. lmerTest package: tests in linear mixed effects models. *Journal of statistical software* **82**, 1-26 (2017).

62     R Core Team, R. R: A language and environment for statistical computing. (2013).

63     Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. & Liechti, M. E. Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. *Clinical Pharmacology & Therapeutics* **n/a**, doi:https://doi.org/10.1002/cpt.2821.

64     Preller, K. H. & Vollenweider, F. X. Phenomenology, Structure, and Dynamic of Psychedelic States. *Curr Top Behav Neurosci* **36**, 221-256, doi:10.1007/7854_2016_459 (2018).

65     Pokorny, T., Preller, K. H., Kraehenmann, R. & Vollenweider, F. X. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. *European Neuropsychopharmacology* **26**, 756-766, doi:https://doi.org/10.1016/j.euroneuro.2016.01.005 (2016).

66    Halberstadt, A. L. *et al.* 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. *Neuropsychopharmacology* **34**, 1958-1967, doi:10.1038/npp.2009.29 (2009).

67    Erkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J. & Ortega, J. E. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. *Biomedicine & Pharmacotherapy* **154**, 113612, doi:https://doi.org/10.1016/j.biopha.2022.113612 (2022).

68    Pędzich, B. D. *et al.* Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice. *Neuropsychopharmacology* **47**, 1304-1314, doi:10.1038/s41386-022-01324-2 (2022).

69    Lawn, T. *et al.* Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD. *Psychopharmacology* **239**, 1797-1808, doi:10.1007/s00213-022-06117-5 (2022).

70    Eshleman, A. J. *et al.* Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. *Psychopharmacology (Berl)* **231**, 875-888, doi:10.1007/s00213-013-3303-6 (2014).

71    Carbonaro, T. M., Johnson, M. W. & Griffiths, R. R. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. *Psychopharmacology* **237**, 2293-2304, doi:10.1007/s00213-020-05533-9 (2020).

72    van Wel, J. H. *et al.* Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. *PLoS One* **7**, e40187, doi:10.1371/journal.pone.0040187 (2012).

73     Rothman, R. B. *et al.* Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse* **39**, 32-41 (2001).

74     Hysek, C. *et al.* The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA ("Ecstasy") in Humans. *Clinical Pharmacology & Therapeutics* **90**, 246-255, doi:https://doi.org/10.1038/clpt.2011.78 (2011).

75     Han, D. D. & Gu, H. H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. *BMC Pharmacol* **6**, 6, doi:10.1186/1471-2210-6-6 (2006).

76     Luethi, D. & Liechti, M. E. Designer drugs: mechanism of action and adverse effects. *Archives of toxicology* **94**, 1085-1133 (2020).

77     Simmler, L. *et al.* Pharmacological characterization of designer cathinones in vitro. *British Journal of Pharmacology* **168**, 458-470, doi:https://doi.org/10.1111/j.1476-5381.2012.02145.x (2013).

78     Hysek, C. M. *et al.* Duloxetine Inhibits Effects of MDMA ("Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study. *PLOS ONE* **7**, e36476, doi:10.1371/journal.pone.0036476 (2012).

79     Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W. & Griffiths, R. R. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. *Psychopharmacology (Berl)* **235**, 2915-2927, doi:10.1007/s00213-018-4981-x (2018).

80     Heitz, R. P. The speed-accuracy tradeoff: history, physiology, methodology, and behavior. *Frontiers in neuroscience* **8**, 150 (2014).

81     Wittmann, M. *et al.* Effects of psilocybin on time perception and temporal control of behaviour in humans. *Journal of Psychopharmacology* **21**, 50-64, doi:10.1177/0269881106065859 (2006).

82      Carter, O. L. *et al.* Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin. *Neuropsychopharmacology* **30**, 1154-1162, doi:10.1038/sj.npp.1300621 (2005).

83      Duerler, P. *et al.* Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study. *Cereb Cortex* **32**, 186-196, doi:10.1093/cercor/bhab202 (2021).

84      Quednow, B. B., Kometer, M., Geyer, M. A. & Vollenweider, F. X. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. *Neuropsychopharmacology* **37**, 630-640 (2012).

85      Carter, O. L. *et al.* Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors. *Journal of Cognitive Neuroscience* **17**, 1497-1508, doi:10.1162/089892905774597191 (2005).

86      Pokorny, T., Duerler, P., Seifritz, E., Vollenweider, F. X. & Preller, K. H. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. *Psychol Med* **50**, 2255-2264, doi:10.1017/s0033291719002393 (2020).

87      van Wel, J. H. P. *et al.* Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment. *Neuropsychopharmacology* **36**, 1932-1939, doi:10.1038/npp.2011.80 (2011).

88      Schmidt, A. *et al.* Acute LSD effects on response inhibition neural networks. *Psychol Med* **48**, 1464-1473, doi:10.1017/s0033291717002914 (2018).

89      Winstanley, C. A., Eagle, D. M. & Robbins, T. W. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. *Clinical psychology review* **26**, 379-395 (2006).

90    Preller, K. H. & Vollenweider, F. X. Modulation of Social Cognition via Hallucinogens and "Entactogens". *Frontiers in Psychiatry* **10**, doi:10.3389/fpsyt.2019.00881 (2019).

91    Doss, M. K. *et al.* Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. *Translational Psychiatry* **11**, 574, doi:10.1038/s41398-021-01706-y (2021).

92    Pacheco, A. T., Olson, R. J., Garza, G. & Moghaddam, B. Acute psilocybin enhances cognitive flexibility in rats. *bioRxiv*, doi:10.1101/2023.01.09.523291 (2023).

93    Sayalı, C. & Barrett, F. S. The costs and benefits of psychedelics on cognition and mood. *Neuron*, doi:https://doi.org/10.1016/j.neuron.2022.12.031 (2023).

94    Mason, N. *et al.* Spontaneous and deliberate creative cognition during and after psilocybin exposure. *Translational psychiatry* **11**, 209 (2021).

95    Kirkpatrick, M. G. *et al.* MDMA effects consistent across laboratories. *Psychopharmacology* **231**, 3899-3905, doi:10.1007/s00213-014-3528-z (2014).

96    de Sousa Fernandes Perna, E. B. *et al.* Safety profile and neurocognitive function following acute 4-fluoroamphetamine (4-FA) administration in humans. *Frontiers in Pharmacology*, 713 (2018).

97    von Rotz, R. *et al.* Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. *eClinicalMedicine* **56**, 101809, doi:https://doi.org/10.1016/j.eclinm.2022.101809 (2023).

98    Yu, C. L. *et al.* Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. *Psychiatry Investig* **18**, 958-967, doi:10.30773/pi.2021.0209 (2021).

99    Theobald, D. S. & Maurer, H. H. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). *Biochem Pharmacol* **73**, 287-297, doi:10.1016/j.bcp.2006.09.022 (2007).

100   Carmo, H. *et al.* Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. *Toxicology* **206**, 75-89, doi:https://doi.org/10.1016/j.tox.2004.07.004 (2005).

101   Kanamori, T., Inoue, H., Iwata, Y., Ohmae, Y. & Kishi, T. In Vivo Metabolism of 4-Bromo-2,5-dimethoxyphenethylamine (2C-B)in the Rat: Identification of Urinary Metabolites. *Journal of analytical toxicology* **26**, 61-66, doi:10.1093/jat/26.2.61 (2002).

102   Studerus, E., Vizeli, P., Harder, S., Ley, L. & Liechti, M. E. Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies. *J Psychopharmacol* **35**, 556-565, doi:10.1177/0269881121998322 (2021).

103   Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W. & Griffiths, R. R. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. *J Psychopharmacol* **35**, 353-361, doi:10.1177/0269881121991822 (2021).

104   Ogungbenro, K. & Aarons, L. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. *J Biopharm Stat* **19**, 174-189, doi:10.1080/10543400802536131 (2009).

105   Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A. & Riba, J. Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. *Psychopharmacology (Berl)* **230**, 415-424, doi:10.1007/s00213-013-3167-9 (2013).

106    Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M. & Olson, D. E. Psychedelics and other psychoplastogens for treating mental illness. *Frontiers in Psychiatry*, 1691 (2021).

107    Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K. & Davoli, C. C. Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. *ACS Pharmacol Transl Sci* **4**, 424-435, doi:10.1021/acsptsci.1c00014 (2021).

108    Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Neuroticism is associated with challenging experiences with psilocybin mushrooms. *Personality and individual differences* **117**, 155-160 (2017).

109    Sessa, B. & Fischer, F. M. Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary. *Drug Science, Policy and Law* **2**, 2050324515578080, doi:10.1177/2050324515578080 (2015).